Breaking News

AstraZeneca to Buy Respiratory Drug Company, Amirall

AZ will acquire the Catalan company, which specializes in drugs for COPD and other respiratory diseases

AstraZeneca has bought the Catalan company, Amirall’s, respiratory therapies business, including rights to Eklira, a drug that is designed to treat chronic obstructive pulmonary disease (COPD) and represents 14.4% of the company’s total sales. The Catalan News Agency reported this news on Wednesday, July 30, 2014. AstraZeneca will reportedly pay $875 million initially, and up to $1.22 billion, depending on product development success, new product launches and sales.  &#8...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters